Cardio-Oncology

Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity. Recent studies have demonstrated…

Although pericardiocentesis of malignant pericardial effusions relieves tamponade, about a third of patients experience recurrence.…

Acute Coronary Syndrome management in cancer patients is challenging due to the complex interplay of…

The clinical effects of sacubitril-valsartan, an angiotensin receptor-neprilysin inhibitor, on anthracycline-induced cardiotoxicity remain unknown. Experimental…

Echocardiograms are recommended every 3 months to monitor for cancer therapy–related cardiac dysfunction (CTRCD) among…

Breast cancer patients often receive cardiotoxic cancer therapy, and have an increased risk of cardiovascular…

Exercise has been shown to reduce cancer recurrence and death rates in observational studies but…

Antibody drug conjugates (ADC) targeting ERBB2 positive breast cancer have improved outcomes, and may even…

Statins are competitive inhibitors of cholesterol biosynthesis and additional derivatives of the mevalonate pathway. For…

Cancer treatments can lead to cancer therapy–related cardiac dysfunction (CTRCD). Sodium glucose cotransporter-2 inhibitors (SGLT2is)…